Investor Presentaiton
*
Q4 FY22: Financial Performance
Total Revenues*
Rs. 38,638 mn
5% YoY
EBITDA & Margin %#
Rs. 8,612 mn
22.3% of revenues
1% YoY
R&D
Rs. 2,697 mn
7% of revenues
Net Profit ex. One-offs
Exceptional & Disc. Ops ^
Rs. 5,250 mn
12% YoY
Total Revenues include net sales and other operating income.
Revenue Break-up (Rs. mn) and YoY Growth
EM
2,750
10%
EU
469
ΑΡΙ Alliances
1,363
1% -2%
633
Total
37,418,
5%
138%
India Form
11,640
14%
Key Highlights of Q4 FY22
Ex-COVID related business, total revenues grew 7% yoy.
zydus
Dedicated To Life
India formulations business continued to display robust performance led
by strong momentum in branded portfolio.
Launched Desidustat (OxemiaTM) in India for the treatment of anemia in
patients with Chronic Kidney Disease (CKD). It is the second NCE
launched, discovered and developed in-house.
On the Specialty front in the US, entered into an asset purchase
agreement with BridgeBio Pharma for acquisition of NULIBRY™
Research & Development (R&D) spend: at Rs.2,697 mn (7% of revenues).
Net debt: Rs. -570 mn (at 31-Mar'22) vs INR 34,862 mn (at 31-Mar'21).
Capex for the quarter: Rs. 2,668 mn and for FY22: Rs. 11,218 mn.
Key Board Meeting Updates
The Board approved buy-back of upto Rs. 7,500 mn at Rs. 650 per equity
share (90% premium to closing share price of 19th May, 2022).
The Board recommended a dividend of 250%.
Note:
US
14,233
-4%
Consumer
# Adjusted for one-time COVID related inventory provision of Rs. 1,435 mn in Q4 FY22
Wellness,
6,330
6%
^ Adjusted for one-time COVID related inventory provision, exceptional and non-recurring items
as well as profit/ loss from discontinued operations.
3View entire presentation